(Press-News.org) SAN FRANCISCO (March 10, 2013) — In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Drug-eluting stents are structures placed inside narrowed coronary arteries to restore proper blood flow. A polymer coating on these devices slowly releases a drug designed to prevent restenosis—another blockage at the same site—and prevent a second invasive procedure to clear the artery, called target lesion revascularization. The polymer's drug greatly reduces restenosis and target lesion revascularization rates, but the coating itself retards healing in the stented artery and may trigger an inflammatory response that leads to late adverse effects. The clinical challenge is to retain the pros of the drug and minimize or eliminate the cons of the polymer. With a polymer coating that dissolves six to nine month after implantation, the biolimus-eluting stent (BES) may reduce late restenosis or very late clotting on the device (stent thrombosis).
The NEXT trial assigned 3,235 patients to either BES or an everolimus-eluting stent (EES) in the largest multicenter, randomized open-label study comparing these two devices ever reported. BES was approved in Japan in 2011, while EES is the country's leading coronary drug-eluting device. The two eluted compounds belong to the same class of drugs. The study enrolled all patients scheduled for insertion of a drug-eluting stent at 98 participating centers in Japan, with no exclusion criteria.
"Our results suggest that BES could be the alternative to EES, a current gold standard second-generation drug-eluting stent," said Masahiro Natsuaki, MD, of Kyoto University Graduate School of Medicine's Department of Cardiovascular Medicine. "Because the polymer will completely disappear one year after stent insertion, at least a three-year timeframe will be needed to demonstrate the potential advantage of BES over other available stents."
BES met the goal of non-inferiority to EES in target-lesion revascularization at one year, with target lesion revascularization in 67 BES patients vs. 66 EES patients (4.2 percent for both groups). The cumulative rates of definite stent thrombosis were low and similar at 0.25 percent in the BES group vs. 0.06 percent in the EES group. In a substudy of 528 patients, angiographic imaging confirmed similar rates of restenosis in both study arms, expressed as late lumen loss—a shrinkage of space inside the stented artery at 266 days + 43 days after the procedure: loss of 0.03+0.39mm in BES patients vs. 0.06+0.45mm in EES patients.
The study's other primary outcome is death or heart attack at three years after stent insertion, with multiple secondary outcome measures for that three-year timeframe. Interim two-year data also will be analyzed.
Many patients in this study were older (mean age 69.2+ 9.8 years), had diabetes (46 percent) or already had a coronary stent (51 percent). Analysis found no differences in outcomes for these subgroups between the two stent types. An earlier study's findings had raised concerns about acute success rate with BES—the ability to deliver all intended stents to the target site and achieve the target artery diameter. In this trial, acute success rates were very high for BES and EES at 99.6 percent in both groups.
Dr. Natsuaki observed that despite the study's all-comer design, the actual study population mostly included patients with stable coronary artery disease; the one-year rate of target lesion revascularization was lower than expected, leading to a relatively large margin of non-inferiority; and the high incidence of follow-up angiography inflated rates of target lesion revascularization. Nevertheless, "Given the equivalent one-year outcome, long-term clinical data for biodegradable-polymer BES compared with durable-polymer EES will have crucial implications for future development of improved metallic drug-eluting stents," he said.
### The study was sponsored by Terumo Japan. Dr. Natsuaki indicated no conflict of interest.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC13 for the latest news from the meeting.
The American College of Cardiology is a nonprofit medical society comprised of 43,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit cardiosource.org.
New biolimus stent equal to everolimus stent at 1 year
Longer-term data needed to show possible superiority of device's disappearing polymer
2013-03-11
ELSE PRESS RELEASES FROM THIS DATE:
Fewer adverse events with 'double kissing' crush stent than culotte
2013-03-11
SAN FRANCISCO (March 10, 2013) — Patients with a type of coronary lesion linked with poor prognosis fared significantly better with the stent technique known as double kissing crush than with culotte stenting, according to data from the DKCRUSH-III trial presented today at the American College of Cardiology's 62nd Annual Scientific Session.
DKCRUSH-III is the first head-to-head comparison of double kissing (DK) crush and culotte stent techniques in coronary artery disease. The study focused on bifurcation lesions, which involve a main branch and a smaller side branch ...
Cangrelor superior to clopidogrel in CHAMPION PHOENIX trial
2013-03-11
SAN FRANCISCO (March 10, 2013) — The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Cangrelor and clopidogrel interfere with the P2Y12 receptor, a platelet-surface protein that helps regulate blood clotting. Currently approved drugs in this class are effective in cutting down ischemic events—blood-flow reductions ...
New anti-clotting drug more effective than current treatment
2013-03-11
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine.
Researchers report that the new drug, which is administered intravenously, reduced the odds of complications from stenting procedures. ...
Magnet ingestion by young children serious and growing problem
2013-03-11
Physicians and parents must be aware of the growing danger of magnet ingestion by children because magnets can adhere to each other and cause life-threatening problems such as bowel perforations, a new case study illustrates in CMAJ.
"Modern magnet technology has transformed what was once an esoteric subtype of foreign-body ingestion into a common and lethal threat," writes Dr. Daniel Rosenfield, Department of Paediatrics, The Hospital for Sick Children (SickKids), with coauthors.
In the past, magnet ingestion generally could be treated with a wait-and-see approach, ...
Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
2013-03-11
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells – without affecting surrounding, healthy cells.
The first study, published today in the journal Oncogene, worked with acute myeloid leukemia (AML), for which current chemotherapies offer a cure rate of only about 55 percent.
"In about 2/3 of all AML patients and about 90 percent of adult AML patients, we found that the Mer receptor was upregulated. Mer receptor protein ...
EARTH: Well-healed faults produce high-frequency earthquake waves
2013-03-11
Alexandria, VA – Much like our voices create sound waves with a variety of low and high pitches, or frequencies, earthquakes produce seismic waves over a broad spectrum. The seismic waves' frequencies determine, in part, how far they travel and how damaging they are to human-made structures. However, the inaccessibility of fault zones means that very little is known about why and how earthquakes produce different frequencies. With the help of a new tabletop model, scientists have now identified how a process known as fault healing can shape seismic waves and potentially ...
BGI Tech develops novel 'Ultra-Deep de novo' assembly solution for heterozygous genomes
2013-03-11
Shenzhen, China, March 11, 2013- BGI Tech Solutions Co., Ltd., also referred to as "BGI Tech", introduced today its novel assembly solution for facilitating heterozygous genomes research. This marks another technological breakthrough for BGI in heterozygous genome assembly after the completed genome sequencing of oyster, diamondback moth and pear.
The availability of a reference genome for a species is the cornerstone for the in-depth understanding of its biological secrets and commercial values. However, a major obstacle that prevents scientists to easily crack the genome ...
Gun retailers take a hard line on illegal firearm sales, UC Davis survey finds
2013-03-11
(SACRAMENTO, Calif.) —A scientific survey of more than 1,600 gun retailers in the U.S. has found that gun buyers frequently try to make illegal purchases and that gun retailers take a dim view of fellow sellers who engage in illegal activity — regardless of whether they are actively breaking the law or simply looking the other way.
The survey, conducted in 2011 by Garen Wintemute, professor of emergency medicine and director of the UC Davis Violence Prevention Research Program, is believed to be the first scientific study of a large group of gun retailers to determine ...
An Internet for robots
2013-03-11
Researchers of five European universities have developed a cloud-computing platform for robots. The platform allows robots connected to the Internet to directly access the powerful computational, storage, and communications infrastructure of modern data centers - the giant server farms behind the likes of Google, Facebook, and Amazon - for robotics tasks and robot learning.
With the development of the RoboEarth Cloud Engine the team continues their work towards creating an Internet for robots. The new platform extends earlier work on allowing robots to share knowledge ...
Researchers solve riddle of what has been holding 2 unlikely materials together
2013-03-11
For years, researchers have developed thin films of bismuth telluride (Bi2Te3) – which converts heat into electricity or electricity to cooling – on top of gallium arsenide (GaAs) to create cooling devices for electronics. But while they knew it could be done, it was not clear how – because the atomic structures of those unlikely pair of materials do not appear to be compatible. Now researchers from North Carolina State University and RTI International have solved the mystery, opening the door to new research in the field.
"We've used state-of-the-art technology to solve ...
LAST 30 PRESS RELEASES:
Six leading organizations unite to launch the pediatric heart transplant alliance
Effect of coupled wing motion on the aerodynamic performance during different flight stages of pigeon
Cercus electric stimulation enables cockroach with trajectory control and spatial cognition training
Day-long conference addresses difficult to diagnose lung disease
First-ever cardiogenic shock academy features simulation lab
Thirty-year mystery of dissonance in the “ringing” of black holes explained
Less intensive works best for agricultural soil
Arctic rivers project receives “national champion” designation from frontiers foundation
Computational biology paves the way for new ALS tests
Study offers new hope for babies born with opioid withdrawal syndrome
UT, Volkswagen Group of America celebrate research partnership
New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll
Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes
University of Cincinnati Cancer Center presents research at AACR 2025
Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025
AACR: Researchers share promising results from MD Anderson clinical trials
New research explains why our waistlines expand in middle age
Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker
Chips off the old block
Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia
Cutting the complexity from digital carpentry
Lung immune cell type “quietly” controls inflammation in COVID-19
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
State and sociodemographic trends in US cigarette smoking with future projections
Young adults drive historic decline in smoking
NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
Chimpanzee stem cells offer new insights into early embryonic development
This injected protein-like polymer helps tissues heal after a heart attack
FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology
In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity
[Press-News.org] New biolimus stent equal to everolimus stent at 1 yearLonger-term data needed to show possible superiority of device's disappearing polymer